BL0175

BL0175 is a nano-medicine (nanoconjugate) under development for cancer therapy, specifically targeting hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer. It is designed to deliver an estrogen receptor inhibitor directly to tumor tissue using nanotechnology. The drug is being developed by Shanghai Best-Link Biosciences (also referred to as Shanghai bestlink Biotechnology). Its mechanism of action appears to involve inhibition of the estrogen receptor pathway; however, the precise molecular target and detailed mechanism have not been fully disclosed in public sources. As of June 2025, BL0175 is in Phase 1 clinical trials[1][2][3][4].